• In late May and early June 2026, Summit Therapeutics and partner Akeso reported new Phase II and Phase III ivonescimab data in colorectal and lung cancer at the ASCO Annual Meeting, while Summit also prepared to present a corporate update at Goldman Sachs’ Global Healthcare Conference.
• The combination of strong objective responses in first-line metastatic colorectal cancer and overall survival benefits in squamous non-small cell lung cancer highlights ivonescimab’s potential reach across multiple solid tumor settings.
• We’ll now examine how ivonescimab’s encouraging colorectal cancer Phase II outcomes may reshape Summit’s investment narrative built around this asset.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Summit Therapeutics Investment Narrative Recap

To own Summit today, you need to believe ivonescimab can convert broad late stage data into approvals and eventual commercial uptake before cash burn becomes a binding constraint. The new colorectal Phase II and HARMONi 6 OS data support that core thesis, but the key near term catalyst still sits with U.S. regulators reviewing the HARMONi BLA, while the biggest risk remains a setback in any major Phase III that could undermine the single asset story.

The AK112 206 metastatic colorectal cancer readout is especially relevant here, because it directly underpins HARMONi GI3, Summit’s global Phase III trial comparing ivonescimab plus mFOLFOX6 to bevacizumab plus mFOLFOX6. If the robust objective responses and early durability in the Phase II setting translate in that registrational study, it could eventually add a second frontline solid tumor pillar alongside NSCLC for this bispecific antibody.

Yet investors should also recognize that if ongoing Phase III trials fail to confirm the survival benefits regulators are looking for, this is information that investors should be aware of...

Summit Therapeutics' narrative projects $848.4 million revenue and $125.2 million earnings by 2029. This implies an earnings increase of about $1.2 billion from -$1.1 billion today.

Uncover how Summit Therapeutics' forecasts yield a $29.18 fair value, a 98% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling about US$3.1 billion of revenue and US$1.7 billion of earnings by 2029, assuming ivonescimab’s large Phase III footprint converts smoothly into approvals and uptake. By contrast, when you weigh those expectations against the very real risk that late stage trials could still throw up less favorable efficacy or safety outcomes, it highlights how wide opinion can be and why it is worth considering multiple viewpoints on Summit’s story.

Explore 6 other fair value estimates on Summit Therapeutics - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Summit Therapeutics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Summit Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Summit Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.